Contributions
Abstract: EP1703
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
The first disease modifying treatment (DMT) option for multiple sclerosis (MS) was started to be used at the end of 1996, in Turkey. The aim of this study was to investigate the effect of the development of treatment options on the MS patient profile, comparing 1996, when no DMT was available, and 2016, when almost every treatment options were available.
This study was conducted retrospectively examining the patient records of Dokuz Eylul MS Clinic. The patient records (all clinic days throughout the year) in 1996 were compared to those in 2016. Patients who applied to the clinic for routine control, and having a clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS) were included. Patients applied to the clinic for a suspected relapse were excluded.
The records including 1929 visits in 1996 were compared to 2245 visits in 2016. The mean frequency of visits were significantly higher in 1996 compared to 2016 (once in 3.7 vs. 5.8 months, p=0.003). No significant difference was found in age and disease duration of the patients visited in 1996 and 2016. There were significantly more number of patients with clinically isolated syndrome (8.2 vs. 3.6%, p=0.004) and SPMS (36.3 vs. 21.4%, p< 0.001) in 1996; however, significantly less number of patients with RRMS (51.4 vs. 70.4%, p< 0.001). The number of patients with the Expanded Disability Status Scale (EDSS) scores of ≤3 were significantly higher in 2016 (68.7 vs. 44.5%, p< 0.001). On the other hand, the number of patients with the EDSS scores of 6-6.5 and ≥7 were significantly less in 2016
(9.2 vs. 21.0% and 3.7 vs. 12.8%, respectively, p< 0.001). Significantly more patients with SPMS, EDSS scores of 6-6.5 and ≥7 (wheel-chair dependent patients) came to the clinic in 1996 compared to 2016 (14.3 vs. 10.0%, 0.006; 8.4 vs. 4.3%, p< 0.001; 5.1 vs. 1.7%, p< 0.001, respectively).
The emergence of treatment options in MS and the increasing availability of new treatment options for patients with no/inadequate treatment response have changed the MS patient profile over the 20 years. The proportion of patients with SPMS and higher EDSS scores reduced. Thus, the number of wheelchair-dependent patients also dramatically reduced. The reduction in the proportion of patients diagnosed with clinically isolated syndrome seems to be related to the narrowing of the clinical definition of clinically isolated syndrome with new diagnostic criteria.
Disclosure:
Serkan Ozakbas: Nothing to disclose
Bilge Piri Cinar: Nothing to disclose
Turhan Kahraman: Nothing to disclose
Gorkem Kosehasanogullari: Nothing to disclose
Abstract: EP1703
Type: ePoster
Abstract Category: Therapy - disease modifying - 28 Long-term treatment monitoring
The first disease modifying treatment (DMT) option for multiple sclerosis (MS) was started to be used at the end of 1996, in Turkey. The aim of this study was to investigate the effect of the development of treatment options on the MS patient profile, comparing 1996, when no DMT was available, and 2016, when almost every treatment options were available.
This study was conducted retrospectively examining the patient records of Dokuz Eylul MS Clinic. The patient records (all clinic days throughout the year) in 1996 were compared to those in 2016. Patients who applied to the clinic for routine control, and having a clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), or primary progressive MS (PPMS) were included. Patients applied to the clinic for a suspected relapse were excluded.
The records including 1929 visits in 1996 were compared to 2245 visits in 2016. The mean frequency of visits were significantly higher in 1996 compared to 2016 (once in 3.7 vs. 5.8 months, p=0.003). No significant difference was found in age and disease duration of the patients visited in 1996 and 2016. There were significantly more number of patients with clinically isolated syndrome (8.2 vs. 3.6%, p=0.004) and SPMS (36.3 vs. 21.4%, p< 0.001) in 1996; however, significantly less number of patients with RRMS (51.4 vs. 70.4%, p< 0.001). The number of patients with the Expanded Disability Status Scale (EDSS) scores of ≤3 were significantly higher in 2016 (68.7 vs. 44.5%, p< 0.001). On the other hand, the number of patients with the EDSS scores of 6-6.5 and ≥7 were significantly less in 2016
(9.2 vs. 21.0% and 3.7 vs. 12.8%, respectively, p< 0.001). Significantly more patients with SPMS, EDSS scores of 6-6.5 and ≥7 (wheel-chair dependent patients) came to the clinic in 1996 compared to 2016 (14.3 vs. 10.0%, 0.006; 8.4 vs. 4.3%, p< 0.001; 5.1 vs. 1.7%, p< 0.001, respectively).
The emergence of treatment options in MS and the increasing availability of new treatment options for patients with no/inadequate treatment response have changed the MS patient profile over the 20 years. The proportion of patients with SPMS and higher EDSS scores reduced. Thus, the number of wheelchair-dependent patients also dramatically reduced. The reduction in the proportion of patients diagnosed with clinically isolated syndrome seems to be related to the narrowing of the clinical definition of clinically isolated syndrome with new diagnostic criteria.
Disclosure:
Serkan Ozakbas: Nothing to disclose
Bilge Piri Cinar: Nothing to disclose
Turhan Kahraman: Nothing to disclose
Gorkem Kosehasanogullari: Nothing to disclose